Skip to content

Author

Nara Samara Silva Felipe dos Santos

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Is a motor phenotype at the first relapse associated with greater disability in multiple sclerosis?

Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system characterized by marked clinical heterogeneity. The phenotype of the first relapse has been investigated as a potential prognostic marker, particularly whether initial motor manifestations are associated wi...

Geane Vasconcellos de Vasconcelos, Nara Samara Silva Felipe dos Santos, Pedro Vítor de Brito Ferreira et al. · 0 citations
Review Open access Oct 2026

Gastrointestinal dysfunction and levodopa therapeutic response in Parkinson’s disease: a Brazilian cross-sectional study

Background: Levodopa therapeutic response depends on factors that determine the optimization of drug absorption and distribution. In this perspective, gastrointestinal disorders in Parkinson's disease (PD), such as constipation and gastroparesis, act as an important barrier to effective treatment, increasing the degrad...

Nara Samara Silva Felipe dos Santos, Geane Vasconcellos de Vasconcelos, Gabriel Teles de Oliveira Piñeiro et al. · 0 citations
Oct 2026

Pre-diagnostic relapse burden predicts disability severity in multiple sclerosis: a dose-response relationship

Background: Multiple sclerosis (MS) is a chronic immune-mediated disease and a leading cause of neurological disability in young adults. Although inflammatory activity early in the disease has been linked to worse outcomes, the independent impact of relapse burden before diagnosis on long-term disability remains unclea...

Pedro Vítor de Brito Ferreira, Luisa Dias Moreno Avarena, Lucca Borges Ornelas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.